title: [Effect of cellular immune supportive treatment on immunity of esophageal carcinoma patients after modern two-field lymph node dissection].
abstract: OBJECTIVE
  Cellular immunity suppression is marked in patients with esophageal carcinoma, which may be resulted temporarily from surgical injury. This study was to evaluate the effect of cellular immune supportive treatment on cellular immunity of patients with esophageal carcinoma.
  
  
  METHODS
  A total of 60 patients with thoracic esophageal carcinoma, received two-field dissection, were randomized into control group and trial (immune supportive treatment) group. The patients in trial group were injected with Shenqi injection after operation; the patients in control group received no immune supportive treatment. Peripheral blood samples were obtained before operation, and 3 and 9 days after operation. AgNOR (argyrophilic nucleolar organizer regions) activity in peripheral blood T lymphocytes was measured by tumor immune microphotometry. T cell subsets were measured by flow cytometry.
  
  
  RESULTS
  The proportions of CD3+CD4+ and CD4+/CD8+ cells were significantly higher in trial group than in control group at 3 days after operation (P < 0.05). The amount of AgNOR and proportions of CD3+, CD3+CD4+, CD4+/CD8+, and CD4+CD25+ cells were significantly higher in trial group than in control group at 9 days after operation (P < 0.05). There was no significant difference in 1-year survival rate between the 2 groups (P > 0.05).
  
  
  CONCLUSIONS
  Shenqi injection could obviously improve cellular immunity of the esophageal carcinoma patients after modern two-field dissection.
authors.affiliation: Skate Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
authors.forename: Jun-Ye
authors.initials: JY
authors.lastname: Wang
authors.forename: Guo-Wei
authors.initials: GW
authors.lastname: Ma
authors.forename: Shu-Qin
authors.initials: SQ
authors.lastname: Dai
authors.forename: Tie-Hua
authors.initials: TH
authors.lastname: Rong
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.forename: Peng
authors.initials: P
authors.lastname: Lin
authors.forename: Wen-Feng
authors.initials: WF
authors.lastname: Ye
authors.forename: Lan-Jun
authors.initials: LJ
authors.lastname: Zhang
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Li
authors.forename: Xu
authors.initials: X
authors.lastname: Zhang
authors.forename: Guang-Yu
authors.initials: GY
authors.lastname: Yao
mesh_terms: D034961:Antigens, Nuclear / Q000097:blood; D027885:Astragalus propinquus / Q000737:chemistry; D017252:CD3 Complex / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016516:CD4-CD8 Ratio; D016827:CD8 Antigens / Q000097:blood; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D004938:Esophageal Neoplasms / Q000276:immunology* / Q000473:pathology* / Q000601:surgery; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007275:Injections, Intravenous; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood; D008197:Lymph Node Excision / Q000379:methods; D008297:Male; D008875:Middle Aged; D005894:Panax / Q000737:chemistry; D010946:Plants, Medicinal / Q000737:chemistry; D011446:Prospective Studies; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000276:immunology*
chemical_list: D034961:Antigens, Nuclear; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D053645:Interleukin-2 Receptor alpha Subunit; C051963:nucleolar organizer region associated proteins